The path(way) less traveled.

Published in Blood

In this issue of Blood, Mathewson et al characterized targeting a novel intracellular pathway with an agent known to induce potent antitumor effects but now also appears to potently suppress inflammatory responses by dendritic cells (DCs) and prevent graft-vs-host disease (GVHD). Identifying agents that can suppress GVHD yet not compromise graft-vs...

Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in mu...

Published in Blood

Natural killer (NK) cells express inhibitory receptors with varied binding affinities to specific major histocompatibility complex class I (MHC-I) haplotypes. NK cells can be classified as licensed or unlicensed based on their ability or inability to bind MHC-I, respectively. The role of donor vs host MHC on their development after allogeneic hemat...

Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immun...

Published in Blood

Memory T cells exhibit tremendous antigen specificity within the immune system and accumulate with age. Our studies reveal an antigen-independent expansion of memory, but not naive, CD8(+) T cells after several immunotherapeutic regimens for cancer resulting in a distinctive phenotype. Signaling through T-cell receptors (TCRs) or CD3 in both mouse ...

The triterpenoid CDDO-Me promotes hematopoietic progenitor expansion and myelopoiesis in mice.

Published in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

The synthetic triterpenoid CDDO-Me has been shown to directly inhibit the growth of myeloid leukemias and lends itself to a wide array of therapeutic indications, including inflammatory conditions, because of its inhibition of NF-κB. We have previously demonstrated protection from acute graft-versus-host disease after CDDO-Me administration in an a...

Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing.

Published in Blood

Natural killer (NK) cells can mediate the rejection of bone marrow allografts and exist as subsets based on expression of inhibitory/activating receptors that can bind MHC. In vitro data have shown that NK subsets bearing Ly49 receptors for self-MHC class I have intrinsically higher effector function, supporting the hypothesis that NK cells undergo...

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.

Published in Journal of immunotoxicology

Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has been modest compared to their theoretical and pre-clinical promise. This review evaluates the promise and pitfalls of immunotherapy and highlight some of the obstacles to im...

Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition

Published in Clinical & Experimental Immunology

Effects of cancer immunotherapy regimens on primary vs. secondary immune responses and the potential impact on long-term...

Published in Adv Exp Med Biol: Crossroads Between Innate and Adaptive Immunity II

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor ...

Published in J Natl Cancer Inst

Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer